JP2024539097A5 - - Google Patents

Info

Publication number
JP2024539097A5
JP2024539097A5 JP2024523434A JP2024523434A JP2024539097A5 JP 2024539097 A5 JP2024539097 A5 JP 2024539097A5 JP 2024523434 A JP2024523434 A JP 2024523434A JP 2024523434 A JP2024523434 A JP 2024523434A JP 2024539097 A5 JP2024539097 A5 JP 2024539097A5
Authority
JP
Japan
Application number
JP2024523434A
Other languages
Japanese (ja)
Other versions
JP2024539097A (ja
JPWO2023069754A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/047491 external-priority patent/WO2023069754A2/en
Publication of JP2024539097A publication Critical patent/JP2024539097A/ja
Publication of JPWO2023069754A5 publication Critical patent/JPWO2023069754A5/ja
Publication of JP2024539097A5 publication Critical patent/JP2024539097A5/ja
Pending legal-status Critical Current

Links

JP2024523434A 2021-10-22 2022-10-21 Gpam発現を阻害するためのrnaiコンストラクト及びその使用方法 Pending JP2024539097A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163270813P 2021-10-22 2021-10-22
US63/270,813 2021-10-22
PCT/US2022/047491 WO2023069754A2 (en) 2021-10-22 2022-10-21 Rnai constructs for inhibiting gpam expression and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2024539097A JP2024539097A (ja) 2024-10-28
JPWO2023069754A5 JPWO2023069754A5 (https=) 2025-11-12
JP2024539097A5 true JP2024539097A5 (https=) 2025-11-12

Family

ID=84360886

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024523434A Pending JP2024539097A (ja) 2021-10-22 2022-10-21 Gpam発現を阻害するためのrnaiコンストラクト及びその使用方法

Country Status (10)

Country Link
EP (1) EP4419682A2 (https=)
JP (1) JP2024539097A (https=)
KR (1) KR20240090496A (https=)
CN (1) CN118525091A (https=)
AU (1) AU2022370883A1 (https=)
CA (1) CA3235262A1 (https=)
CL (1) CL2024001214A1 (https=)
IL (1) IL311839A (https=)
MX (1) MX2024004913A (https=)
WO (1) WO2023069754A2 (https=)

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
DE69233501T2 (de) 1991-11-22 2006-02-23 Affymetrix, Inc. (n.d.Ges.d.Staates Delaware), Santa Clara Kombinatorische Strategien für die Polymersynthese
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
ATE285477T1 (de) 1995-06-07 2005-01-15 Inex Pharmaceutical Corp Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
DE69834038D1 (de) 1997-07-01 2006-05-18 Isis Pharmaceutical Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
WO2000003683A2 (en) 1998-07-20 2000-01-27 Inex Pharmaceuticals Corporation Liposomal encapsulated nucleic acid-complexes
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US6693187B1 (en) 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
US20030130186A1 (en) 2001-07-20 2003-07-10 Chandra Vargeese Conjugates and compositions for cellular delivery
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
WO2003093449A2 (en) 2002-05-06 2003-11-13 Nucleonics, Inc. Methods for delivery of nucleic acids
US8017762B2 (en) 2003-04-17 2011-09-13 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
US7723509B2 (en) 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
DK1620544T3 (en) 2003-04-17 2019-01-14 Alnylam Pharmaceuticals Inc MODIFIED iRNA AGENTS
US7851615B2 (en) 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
CA2685127C (en) 2007-04-23 2019-01-08 Alnylam Pharmaceuticals, Inc. Glycoconjugates of rna interference agents
WO2009082607A2 (en) 2007-12-04 2009-07-02 Alnylam Pharmaceuticals, Inc. Targeting lipids
EP2310504A1 (en) * 2008-07-03 2011-04-20 Santaris Pharma A/S Rna antagonist compounds for the inhibition of expression of mitochondrial glycerol-3-phosphate acyltransferase 1 (mtgpat1)
WO2011103516A2 (en) * 2010-02-18 2011-08-25 The Trustees Of Princeton University Inhibitors of long and very long chain fatty acid metabolism as broad spectrum anti-virals
US20140275211A1 (en) 2011-06-21 2014-09-18 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
AR090905A1 (es) 2012-05-02 2014-12-17 Merck Sharp & Dohme Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica
EP3564374A1 (en) 2013-06-21 2019-11-06 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids

Similar Documents

Publication Publication Date Title
CA3225073A1 (https=)
BR102022025291A2 (https=)
JP2024539097A5 (https=)
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
CN307048257S (https=)
CN307047554S (https=)
CN307047785S (https=)
BY13149U (https=)
BY13135U (https=)
BY13169U (https=)
BY13137U (https=)
BY13140U (https=)